Personalized pain pills: gene test may cut opioid risks after hernia repair

NCT ID NCT06565546

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests whether using a genetic test (CYP2D6) to choose pain medications can improve pain control and quality of life for 100 adults undergoing elective ventral hernia repair. Participants receive either standard pain meds or meds guided by their genetic profile. The goal is to see if this personalized approach is feasible and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CYP2D6 genotype testing to guide opioid pain medication
What this could lead to
If successful, this could lead to personalized pain management that reduces side effects and improves recovery after hernia surgery.
What could go wrong
This is a small pilot study (100 people) testing feasibility, not effectiveness. Genetic testing may not improve pain control for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRAL HERNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hernia, Ventral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Florida Jacksonville

    Jacksonville, Florida, 32209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.